Dynamics of platelet hemostasis indices in patients with cardioembolic stroke against the background of atrial fibrillation

Galkin S.S.; Gunchenko A.S.; Abdukhalikova Zh.; Yutskova E.V.; Anisimova A.V.

doi:https://doi.org/10.17116/jnevro202112112262

Galkin S.S.

Pirogov Russian National Research Medical University

Gunchenko A.S.

Pirogov Russian National Research Medical University

Abdukhalikova Zh.

Pirogov Russian National Research Medical University;
Pirogov City Clinical Hospital No. 1

Yutskova E.V.

Pirogov City Clinical Hospital No. 1

Anisimova A.V.

Pirogov Russian National Research Medical University;
Pirogov City Clinical Hospital No. 1

Dynamics of platelet hemostasis indices in patients with cardioembolic stroke against the background of atrial fibrillation

Authors:

Galkin S.S., Gunchenko A.S., Abdukhalikova Zh., Yutskova E.V., Anisimova A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12‑2): 62‑68

DOI: 10.17116/jnevro202112112262

Read: 1908 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Galkin SS, Gunchenko AS, Abdukhalikova Zh, Yutskova EV, Anisimova AV. Dynamics of platelet hemostasis indices in patients with cardioembolic stroke against the background of atrial fibrillation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12‑2):62‑68. (In Russ.)
https://doi.org/10.17116/jnevro202112112262

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the parameters of platelet hemostasis in patients with cardioembolic ischemic stroke on the background of atrial fibrillation and taking warfarin to assess the effectiveness of antiplatelet drugs in the prevention of recurrent ischemic strokes.

MATERIAL AND METHODS

93 patients with ischemic stroke on the background of atrial fibrillation were examined, of which the main group consisted of 43 patients who took warfarin and 50 patients from the reference group without warfarin. The study of the platelet link of hemostasis using inductors (adrenaline, ristomycin, arachidonic acid, collagen, ADP) in patients of both groups was carried out. In the group of patients taking warfarin there was a significant increase in platelet aggregation for adrenaline up to 57.15 [29.51; 62.61] (p=0.0315), spontaneous aggregation 2.46 [1.39; 6.75] (p=0.047), reduction of platelet aggregation for collagen 14.45 [4.80; 43.63] (p=0.008). In 35 patients of the study group (n=93), laboratory resistance to aspirin was also revealed in terms of platelet aggregation to arachidonic acid, which is a criterion for evaluating the effectiveness of preventive measures for recurrent ischemic strokes with antiplatelet drugs.

CONCLUSION

The obtained data are additional risk factors for recurrent strokes. It is also recommended to study platelet aggregation for arachidonic acid to assess the effectiveness of antiplatelet drugs prophylaxis of recurrent ischemic strokes.

Keywords:

cardioembolic stroke

atrial fibrillation

platelet hemostasis

warfarin

primary prevention

secondary prevention

Authors:

Galkin S.S.

Pirogov Russian National Research Medical University

Gunchenko A.S.

Pirogov Russian National Research Medical University

Abdukhalikova Zh.

Pirogov Russian National Research Medical University;
Pirogov City Clinical Hospital No. 1

Yutskova E.V.

Pirogov City Clinical Hospital No. 1

Anisimova A.V.

Pirogov Russian National Research Medical University;
Pirogov City Clinical Hospital No. 1

Received:

14.12.2020

Accepted:

02.07.2021

Close metadata

References:

Klochikhina OA, Stakhovskaya LV, Polunina EA, et al. Epidemiology and prognosis of the incidence and mortality rate from stroke in different age groups according to the territorial-population register. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8-2):5-12. (In Russ.). https://doi.org/10.17116/jnevro20191190825
Shpektor AV, Vasilyeva EYu, Shamalov NA, et al. Organization of the system of endovascular care for patients with ischemic stroke in Moscow. In: Prize of the City of Moscow in the field of medicine. Collection of abstracts of scientific papers submitted for the award of the prize in 2019. Khripun AI, ed. 2019:31-32. (In Russ.).
Botsina AYu, Sukhanova EO, Anisimov KV, et al. Application of methods of reperfusion therapy in patients with ischemic stroke in the hospital of the Moscow stroke network (Davydovsky City Clinical Hospital). Moscow Medicine. 2019;6(34):24-25. (In Russ.).
Anisimov KV, Shamalov NA, Manchurov VN, et al. Features of thromboextraction from large-diameter arteries in patients with ischemic stroke (a series of clinical observations). Endovascular Surgery. 2019;6(3):242-255. (In Russ.). https://doi.org/10.24183/2409-4080-2019-6-3-242-255
Geraskina LA, Alieva MM, Fonyakin AV, et al. Pathogenetic heterogeneity of ischemic stroke in atrial fibrillation. Bulletin of the Russian Military Medical Academy. 2019;3:36-38. (In Russ.). https://doi.org/10.32863/1682-7392-2019-3-67-36-38
Khakhanova ON, Skorokhodov AP, Kutashov VA, Ulyanova OV. Cardioembolic stroke: risk factors, prognosis, secondary prevention. Saratov Journal of Medical Scientific Research. 2017;13(1):187-192. (In Russ.).
Vorobieva NA, Vorobieva AI, Shemyakina NYa, Alekseeva AS. Patient-oriented approach as a basis for increasing the efficiency and safety of antithrombotic therapy in comorbid patients. The role of anticoagulant rooms. Clinical Gerontology. 2019;25(11-12):19-24. (In Russ.). https://doi.org/10.26347/1607-2499201911-12019-024
Vavilova TV, Solovieva LV, Bekoeva AB, et al. Best practices of the Russian Federation in the organization of anticoagulant therapy in patients with high risk of thromboembolic complications. Russian Journal of Cardiology. 2020;25(6):10-14. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3945
Baranova EI, Kobalava ZhD. Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations. Russian Journal of Cardiology. 2019;24(11):133-141. (In Russ.). https://doi.org/10.15829/1560-4071-2019-11-133-141
Kobalava ZhD, Shavarov AA. The nuances of anticoagulant therapy in patients with chronic kidney disease and atrial fibrillation. Cardiology. 2018;58(10):59-70. (In Russ.). https://doi.org/10.18087/cardio.2018.10.10185
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 July;52(7):e364-e467. Epub 2021 May 24. https://doi.org/10.1161/STR.0000000000000375
Kalinin MN, Khasanova DR, Ibatullin MM. Possible timing of initiation of anticoagulant therapy in patients with ischemic stroke and atrial fibrillation: a subsequent analysis of the Hemorrhagic Transformation Index. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):12-21. (In Russ.). https://doi.org/10.14412/2074-2711-2019-2-12-21
Anisimova AV, Galkin SS, Buslaeva EV, Kapelnitsky PV. The prognostic significance of the parameters of the platelet hemostasis in patients with ischemic stroke after systemic thrombolytic therapy. Materials of the XI All-Russian Congress of Neurologists and the IV Congress of the National Association for Stroke Control. St. Petersburg, June 15-19, 2019. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):568. (In Russ.). https://doi.org/10.17116/jnevro201911905S
Fure B, Wyller TB, Thommessen B. TOAST criteria applied in acute ischemic stroke. Acta Neurol Scand. 2005;112:254-258. https://doi.org/10.1111/j.1600-0404.2005.00470
Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864-870. https://doi.org/10.1161/01.str.20.7.864
Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-965. https://doi.org/10.1016/s0735-1097(02)03014-0
Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363-368. https://doi.org/10.1161/01.CIR.103.3.363
Chen W-H, Lee PY, Ng W, et al. Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol. 2005;45:382-386.
Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J. 2006;27:647-654. https://doi.org/10.1093/eurheartj/ehi684
Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 2006;12(2): 251-258. https://doi.org/10.2174/138161206775193064
Tanashyan MM, Domashenko MA, Raskurazhev AA. Aspirin resistance: clinical and molecular genetic evaluation techniques. Annals of Clinical and Experimental Neurology. 2016;10(1):41-46. (In Russ.).